20-22 August 2018

This unique IPF meeting is your opportunity to join the leading minds across biopharma and academia to reduce the expansive translational gap that exists in current IPF drug development.

IPF Summit 2017 brought over 90 of the leading minds across biopharma and academia together to discuss shortening the translational gap that exists in current IPF drug development. Sessions enabled attendees to:

  • Effectively translate into the clinic by better recapitulating IPF through robust in vitro & vivo models
  • Define more meaningful preclinical endpoints to aid identification of novel targets and development of more effective IPF therapeutics
  • Validate non-invasive biomarker & diagnostic techniques for back translation and ultimately achieve greater clinical benefit

The Idiopathic Pulmonary (IPF) Summit is the only event solely dedicated to transforming discovery & translational fibrosis research into disease modifying IPF therapeutics.

Find out more.

"This conference was of outstanding value. First class presentations, great opportunity for networking and perfect logistics!” AstraZeneca - Previous Hanson Wade Life Sciences event attendee

This  Summit is for:

  • Large Pharma
  • Biotech
  • Academics looking to
    network with industry
  • Preclinical model providers
  • CROs
IPF Boehringer Ingelheim

 

 

 

 

 

Media Partner